Logo image of NKTR

NEKTAR THERAPEUTICS (NKTR) Stock Fundamental Analysis

NASDAQ:NKTR - Nasdaq - US6402681083 - Common Stock - Currency: USD

0.7383  +0.05 (+7.66%)

After market: 0.75 +0.01 (+1.58%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NKTR. NKTR was compared to 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for NKTR as it has an excellent financial health rating, but there are worries on the profitability. NKTR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NKTR had negative earnings in the past year.
In the past year NKTR has reported a negative cash flow from operations.
NKTR had negative earnings in each of the past 5 years.
In the past 5 years NKTR always reported negative operating cash flow.
NKTR Yearly Net Income VS EBIT VS OCF VS FCFNKTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

With a Return On Assets value of -39.15%, NKTR perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
Looking at the Return On Equity, with a value of -195.86%, NKTR is doing worse than 68.18% of the companies in the same industry.
Industry RankSector Rank
ROA -39.15%
ROE -195.86%
ROIC N/A
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
NKTR Yearly ROA, ROE, ROICNKTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

With a decent Gross Margin value of 68.82%, NKTR is doing good in the industry, outperforming 74.24% of the companies in the same industry.
NKTR's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NKTR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
NKTR Yearly Profit, Operating, Gross MarginsNKTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

7

2. Health

2.1 Basic Checks

NKTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NKTR has been reduced compared to 1 year ago.
NKTR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NKTR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NKTR Yearly Shares OutstandingNKTR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
NKTR Yearly Total Debt VS Total AssetsNKTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -16.53, we must say that NKTR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -16.53, NKTR is not doing good in the industry: 79.80% of the companies in the same industry are doing better.
NKTR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.53
ROIC/WACCN/A
WACC9.66%
NKTR Yearly LT Debt VS Equity VS FCFNKTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 4.26 indicates that NKTR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.26, NKTR is in the better half of the industry, outperforming 66.16% of the companies in the same industry.
NKTR has a Quick Ratio of 4.26. This indicates that NKTR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NKTR (4.26) is better than 67.68% of its industry peers.
Industry RankSector Rank
Current Ratio 4.26
Quick Ratio 4.26
NKTR Yearly Current Assets VS Current LiabilitesNKTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.71% over the past year.
The Revenue has grown by 9.26% in the past year. This is quite good.
NKTR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.00% yearly.
EPS 1Y (TTM)25.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.27%
Revenue 1Y (TTM)9.26%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%22.15%

3.2 Future

The Earnings Per Share is expected to grow by 3.75% on average over the next years.
Based on estimates for the next years, NKTR will show a quite strong growth in Revenue. The Revenue will grow by 9.37% on average per year.
EPS Next Y13.66%
EPS Next 2Y-2.23%
EPS Next 3Y-5.3%
EPS Next 5Y3.75%
Revenue Next Year-26.36%
Revenue Next 2Y-16.73%
Revenue Next 3Y-6.97%
Revenue Next 5Y9.37%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NKTR Yearly Revenue VS EstimatesNKTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
NKTR Yearly EPS VS EstimatesNKTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NKTR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NKTR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKTR Price Earnings VS Forward Price EarningsNKTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKTR Per share dataNKTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as NKTR's earnings are expected to decrease with -5.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.23%
EPS Next 3Y-5.3%

More info and screens

0

5. Dividend

5.1 Amount

NKTR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEKTAR THERAPEUTICS

NASDAQ:NKTR (4/24/2025, 8:00:02 PM)

After market: 0.75 +0.01 (+1.58%)

0.7383

+0.05 (+7.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12 2025-03-12/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners72.56%
Inst Owner Change-0.03%
Ins Owners1.3%
Ins Owner Change9.79%
Market Cap137.40M
Analysts78.57
Price Target4.85 (556.91%)
Short Float %3.64%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.54%
Min EPS beat(2)6.77%
Max EPS beat(2)16.31%
EPS beat(4)3
Avg EPS beat(4)1.16%
Min EPS beat(4)-20.38%
Max EPS beat(4)16.31%
EPS beat(8)4
Avg EPS beat(8)-4.04%
EPS beat(12)8
Avg EPS beat(12)5.9%
EPS beat(16)12
Avg EPS beat(16)6.6%
Revenue beat(2)1
Avg Revenue beat(2)12.58%
Min Revenue beat(2)-4.21%
Max Revenue beat(2)29.38%
Revenue beat(4)3
Avg Revenue beat(4)23.67%
Min Revenue beat(4)-4.21%
Max Revenue beat(4)38.28%
Revenue beat(8)6
Avg Revenue beat(8)16.78%
Revenue beat(12)7
Avg Revenue beat(12)10.6%
Revenue beat(16)8
Avg Revenue beat(16)6.52%
PT rev (1m)0%
PT rev (3m)1.06%
EPS NQ rev (1m)6.4%
EPS NQ rev (3m)20.61%
EPS NY rev (1m)17.38%
EPS NY rev (3m)14.97%
Revenue NQ rev (1m)3.61%
Revenue NQ rev (3m)-24.08%
Revenue NY rev (1m)-14.4%
Revenue NY rev (3m)-17.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.4
P/FCF N/A
P/OCF N/A
P/B 2.26
P/tB 2.26
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.53
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.15%
ROE -195.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.82%
FCFM N/A
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.43%
Cap/Sales 1.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.26
Quick Ratio 4.26
Altman-Z -16.53
F-Score4
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)29.45%
Cap/Depr(5y)49.23%
Cap/Sales(3y)2.88%
Cap/Sales(5y)5.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.27%
EPS Next Y13.66%
EPS Next 2Y-2.23%
EPS Next 3Y-5.3%
EPS Next 5Y3.75%
Revenue 1Y (TTM)9.26%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%22.15%
Revenue Next Year-26.36%
Revenue Next 2Y-16.73%
Revenue Next 3Y-6.97%
Revenue Next 5Y9.37%
EBIT growth 1Y3.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.64%
EBIT Next 3Y-8.45%
EBIT Next 5YN/A
FCF growth 1Y8.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.77%
OCF growth 3YN/A
OCF growth 5YN/A